The Biden administration has denied a petition that would have reduced the price of Xtandi, a drug developed at the University of California, Los Angeles, to treat prostate cancer.
Read the full post on Becker's Hospital Review - Healthcare News
Biden administration will not pursue action to lower cancer drug price
